相关实验视频

Updated: Jun 21, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.2K

乳腺癌中雌激素受体异常的临床,病理和基因表达分析

Xi Wang1, Shengnan Bao2, Mengping Jiang1

  • 1Department of Radiotherapy, Affiliated Hospital 2 of Nantong University (Nantong First People's Hospital), Nantong, 226300, Jiangsu, China.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|June 26, 2024
PubMed
概括

基因KMT2C可能通过影响分子和免疫因素来驱动乳腺癌的进展和对激素治疗的耐药性. 对于雌激素受体阴性乳腺癌患者,KMT2C显示出作为预后生物标志物的潜力.

关键词:
雌激素受体异调异调是一种异调.转移性乳腺癌是发生转移的这是下一代测序.精准医学是一门精准的医学.

更多相关视频

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

10.5K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...